Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Year: 2010
Type: article
Source: Clinical Cancer Research
Institutions: Cleveland Clinic, Institut Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: advanced renal cell carcinoma, sorafenib, prognostic factors, treatment response biomarkers, vascular endothelial growth factor, soluble VEGFR-2, carbonic anhydrase IX, TIMP-1, p21ras, VHL mutation, plasma proteins, survival prediction, ECOG performance status, transarterial chemoembolization
Open Access status: closed
Funders: Bayer HealthCare, Onyx Pharmaceuticals
OpenAlex ID: W2135400147
